Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology • Colorectal Cancer • Journal Club ft. Lancet publication
Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?
The primary nivo/ipi arm was q3 wks x4c, whereas the post-chemo crossover arm used q6 wks until progression. Is one schedule clearly more effective or safer than the other, or is it dealer's choice?
Answer from: Medical Oncologist at Academic Institution
Before the CheckMate 8HW reported data compared nivolumab/ipilimumab vs nivolumab, the strongest evidence we have is from the indirect comparison from the two later-line arms, including the phase II CheckMate142 study (Lenz et al, PMID: 34637336) which showed response rates for nivolumab and ni...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
As ipilimumab often drives the increased toxicity of dual checkpoint inhibitors in comparison to monotherapy, multiple dosing regimens have been used across tumor types. Patients tend to do better with either short courses of ipilimumab (such as the Q3 week dosing for 4 cycles) or longer periods bet...